OverviewSuggest Edit

Intellia is a genome editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. This technology offers the potential to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. Intellia's combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.

TypePublic
Founded2014
HQCambridge, MA, US
Websiteintelliatx.com
Employee Ratings4.1
Overall CultureA-

Latest Updates

Employees (est.) (Feb 2020)270(+28%)
Job Openings83
Revenue (FY, 2020)$58 M(+35%)
Share Price (Nov 2021)$132.2(+2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Intellia Therapeutics

John Leonard

John Leonard

President, Chief Executive Officer & Director
Eliana Clark

Eliana Clark

Senior Vice President, Technical Operations
Glenn Goddard

Glenn Goddard

Executive Vice President, Chief Financial Officer
David Lebwohl

David Lebwohl

Executive Vice President, Chief Medical Officer
Fred Cohen

Fred Cohen

Independent Director
James Basta

James Basta

Executive Vice President, General Counsel and Corporate Secretary
Show more

Intellia Therapeutics Office Locations

Intellia Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
40 Erie St #130
Show all (1)

Intellia Therapeutics Financials and Metrics

Intellia Therapeutics Revenue

Intellia Therapeutics's revenue was reported to be $57.99 m in FY, 2020
USD

Revenue (Q1, 2021)

6.4m

Net income (Q1, 2021)

(46.2m)

EBIT (Q1, 2021)

(46.4m)

Market capitalization (12-Nov-2021)

9.6b

Closing stock price (12-Nov-2021)

132.2

Cash (31-Mar-2021)

141.5m

EV

9.5b
Intellia Therapeutics's current market capitalization is $9.6 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

30.4m43.1m58.0m

Cost of goods sold

Gross profit

30.4m43.1m58.0m

Gross profit Margin, %

100%100%100%
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

7.7m7.4m10.4m11.1m10.6m12.9m16.3m22.2m6.4m

Cost of goods sold

Gross profit

10.4m

Gross profit Margin, %

100%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

273.1m340.7m58.9m57.2m160.0m

Accounts Receivable

6.5m10.5m7.5m4.6m2.1m

Prepaid Expenses

3.7m3.4m5.1m17.0m

Inventories

1.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(10.6b)(67.5m)(85.3m)(99.5m)(134.2m)

Depreciation and Amortization

3.0k3.0m4.5m

Inventories

(285.0k)

Accounts Payable

163.0k(488.0k)232.0k1.9m5.1m
USDQ1, 2016

Financial Leverage

-2.8 x
Show all financial metrics

Intellia Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Intellia Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Intellia Therapeutics Online and Social Media Presence

Embed Graph

Intellia Therapeutics Company Culture

  • Overall Culture

    A-

    76/100

  • CEO Rating

    A+

    85/100

  • Compensation

    A+

    91/100

Learn more on Comparably

Intellia Therapeutics News and Updates

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically …

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of data from its ex viv…

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported financial results for the third quarter e…

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2021 financial results an…

Thinking about trading options or stock in Quest Diagnostics, Qualtrics International, Humana, Intellia Therapeutics, or MicroStrategy?

NEW YORK, Oct. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DGX, XM, HUM, NTLA, and MSTR. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the U.S. Food and Drug Administrati…
Show more

Intellia Therapeutics Blogs

Debjit Chattopadhyay guggenheimpartners.com

Debjit Chattopadhyay guggenheimpartners.com John.Bissaillo… Tue, 10/05/2021 - 10:52 Debjit Chattopadhyay Guggenheim Partners Debjit.Chattopadhyay@guggenheimpartners.com

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock Content Import Fri, 07/02/2021 - 16:01 Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock Jul 2, 2021 This release i…

Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean reduction in serum TTR, with a maximum 96% serum TTR reduction by day 28, with dose-dependent response

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

Focus will be on Development of Allogeneic Universal CAR T-Cell Therapies for Immuno -oncology and Autoimmune Diseases - Blackstone Life Sciences Commits to an Active Role and a $250 Million Financing as Sole Founding Investor - Cellex to Contribute Switchable Universal CAR-T Technology Developed

RBC – Luca Issi – please add this analyst (lucca.issi@rbccm.com

RBC – Luca Issi – please add this analyst (lucca.issi@rbccm.com John.Bissaillo… Thu, 06/17/2021 - 10:17 Luca Issi RBC lucca.issi@rbccm.com

H.C. Wainwright & Co. – Michael G. King Jr

H.C. Wainwright & Co. – Michael G. King Jr John.Bissaillo… Fri, 06/11/2021 - 11:42 Michael G. King Jr H.C. Wainwright & Co. mking@hcwco.com
Show more

Intellia Therapeutics Frequently Asked Questions

  • When was Intellia Therapeutics founded?

    Intellia Therapeutics was founded in 2014.

  • Who are Intellia Therapeutics key executives?

    Intellia Therapeutics's key executives are John Leonard, Eliana Clark and Glenn Goddard.

  • How many employees does Intellia Therapeutics have?

    Intellia Therapeutics has 270 employees.

  • What is Intellia Therapeutics revenue?

    Latest Intellia Therapeutics annual revenue is $58 m.

  • What is Intellia Therapeutics revenue per employee?

    Latest Intellia Therapeutics revenue per employee is $214.8 k.

  • Who are Intellia Therapeutics competitors?

    Competitors of Intellia Therapeutics include Ionis Pharmaceuticals, 4D Molecular Therapeutics and Omega Therapeutics.

  • Where is Intellia Therapeutics headquarters?

    Intellia Therapeutics headquarters is located at 40 Erie St #130, Cambridge.

  • Where are Intellia Therapeutics offices?

    Intellia Therapeutics has an office in Cambridge.

  • How many offices does Intellia Therapeutics have?

    Intellia Therapeutics has 1 office.